Evodiamine and Rutaecarpine Inhibit Migration by LIGHT Via Suppression of NADPH Oxidase Activation
Evodiamine and Rutaecarpine Inhibit Migration by LIGHT Via Suppression of NADPH Oxidase Activation
复制标题
DOI：
10.1002/jcb.22109
复制
发表时间：
2009-05-01
影响因子：
4
通讯作者：
Park, Sun-Dong
中科院分区：
文献类型：
--
作者：
Heo, Sook-Kyoung;Yun, Hyun-Jeong;Park, Sun-Dong
光在动脉粥样硬化发生中起了新的作用。吴茱萸（Evodia Fructus， EF）的干燥、未成熟的果实长期以来一直被用作传统的中草药，目前广泛用于治疗头痛、腹痛、呕吐、感冒和血液循环不畅。evolodiamine和rutaecarpine是EF的活性成分。在这项研究中，我们研究了evolodiamine和rutaecarpine对人单核细胞光诱导迁移的抑制作用。Evodiamine和rutacarpine降低了光诱导的ROS、IL-8、单核细胞趋化蛋白-1 （MCP-1）、tnf - α和IL-6的产生，以及趋化因子受体（CCR） 1、CCR2和ICAM-1的表达和ERK 1/2和p38 MAPK的磷酸化。此外，NADPH氧化酶组装抑制剂AEBSF可以阻断光诱导的CCR1、CCR2、ICAM-1和MAPK（如ERK和p38）的迁移和激活，其方式类似于evodiamine和rutaecarpine。这些发现表明，通过减少ROS的产生和NADPH氧化酶的激活，evodiamine和rutaecarpine对光诱导迁移和CCR1、CCR2、ICAM-1、ERK和p3B MAPK的激活具有抑制作用。综上所述，这些结果表明，evoldiamine和rutacarpine有潜力作为抗动脉粥样硬化剂。j .细胞。生物化学学报，29(2):393 - 393,2009。(C) 2009 Wiley-Liss, Inc。
LIGHT acted as a new player in the atherogenesis. The dried, unripe fruit of Evodia Fructus (EF) has long been used as a traditional Chinese herbal medicine, and is currently widely used for the treatment of headache, abdominal pain, vomiting, colds and reduced blood circulation. Evodiamine and rutaecarpine are active components of EF. In this study, we investigated the inhibitory effect of evodiamine and rutaecarpine on LIGHT-induced migration in human monocytes. Evodiamine and rutaecarpine decreased the LIGHT-induced production of ROS, IL-8, monocyte chemoattractant protein-1 (MCP-1), TNF-alpha, and IL-6, as well as the expression of chemokine receptor (CCR) 1, CCR2 and ICAM-1 and the phosphorylation of the ERK 1/2 and p38 MAPK. Furthermore, NADPH oxidase assembly inhibitor, AEBSF, blocked LIGHT-induced migration and activation of CCR1, CCR2, ICAM-1, and MAPK such as ERK and p38 in a manner similar to evodiamine and rutaecarpine. These findings indicate that the inhibitory effects of evodiamine and rutaecarpine on LIGHT-induced migration and the activation of CCR1, CCR2, ICAM-1, ERK, and p3B MAPK occurs via decreased ROS production and NADPH oxidase activation. Taken together, these results indicate that evodiamine and rutaecarpine have the potential for use as an anti-atherosclerosis agent. J. Cell. Biochem. 107: 123-133, 2009. (C) 2009 Wiley-Liss, Inc.